SenesTech, Inc. reported its financial results for the second quarter and first half of 2025, revealing a net revenue of $625,000 for the three months ending June 30, 2025, a 36% increase from $459,000 in the same period of 2024. For the first half of 2025, revenues reached $1.11 million, up 27% from $874,000 in the first half of 2024. The company attributed this growth primarily to increased sales of its Evolve product line, which accounted for approximately 83% of second-quarter revenues, compared to 58% in the prior year. Despite the revenue increase, SenesTech reported a net loss of $1.62 million for the second quarter, slightly higher than the $1.58 million loss in the same quarter of 2024.
The company's financial position showed significant improvement, with total current assets rising to $7.47 million as of June 30, 2025, compared to $2.81 million at the end of 2024. Cash and cash equivalents increased to $6.06 million from $1.31 million over the same period. Total liabilities decreased to $3.39 million from $767,000, while stockholders' equity rose to $6.98 million from $2.51 million. The increase in equity was driven by the issuance of common stock and warrants, which generated substantial cash inflow.
Operationally, SenesTech has made strategic advancements, including the launch of its Evolve product line, which includes Evolve Rat and Evolve Mouse, aimed at fertility control in rodent populations. The company has also relocated to a new manufacturing facility to enhance production capacity. As of June 30, 2025, SenesTech reported a total employee headcount of 30, reflecting its ongoing efforts to build a capable workforce to support its growth initiatives.
Looking ahead, SenesTech anticipates continued operating losses as it invests in the commercialization of its products and seeks regulatory approvals. The company expects its current cash reserves, combined with anticipated revenues and potential future equity sales, to be sufficient to fund operations through at least the end of fiscal 2027. However, management acknowledged the need for additional financing to support ongoing operating losses and research and development activities, emphasizing that without adequate funding, the company may face challenges in continuing its operations.
About SenesTech, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.